Contusugene ladenovec for the treatment of recurrent unresectable squamous cell carcinoma of the head and neck [ID76]
Discontinued
Reference number: GID-TAG407
Following on from information provided to NICE by the company in August 2009, the appraisal of Head and neck cancer - contusugene ladenovec [ID76] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.